{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:06:28Z","timestamp":1791378388836,"version":"4.3.2"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 105-2314-B-006-045-MY2"],"award-info":[{"award-number":["MOST 105-2314-B-006-045-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004844","name":"National Cheng Kung University Hospital","doi-asserted-by":"publisher","award":["NCKUH-10902063"],"award-info":[{"award-number":["NCKUH-10902063"]}],"id":[{"id":"10.13039\/501100004844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The literature regarding pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy (IMRT) for esophageal cancer was lacking. This study aimed to investigate the risk factors of pericardial effusion in esophageal cancer patients undergoing definitive concurrent chemotherapy and IMRT.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A total of 126 consecutive esophageal cancer patients treated with definitive concurrent chemotherapy and IMRT between 2008 and 2018 were reviewed. The pericardial effusion was determined on computed tomography scan of the chest and graded by the Common Terminology Criteria for Adverse Events, version 4.0. The cumulative incidence of pericardial effusion was estimated by the Kaplan\u2013Meier method and compared between groups by the log-rank test. The risk factors of pericardial effusion were determined with multivariate Cox proportional hazards regression analysis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The median follow-up time was 14.0\u2009months. Thirty-seven (29.4%) patients had pericardial effusion after a median interval of 6.6\u2009months since the end of IMRT. The cumulative incidence of pericardial effusion of any grade was higher in patients with mean heart dose &gt;\u200923.45\u2009Gy (<jats:italic>p<\/jats:italic>\u2009=\u20090.00018), heart V30\u2009&gt;\u200933.55% (<jats:italic>p<\/jats:italic>\u2009=\u20090.00015), mean pericardium dose &gt;\u200920.33\u2009Gy (<jats:italic>p<\/jats:italic>\u2009=\u20090.00027), and pericardium V20\u2009&gt;\u200942.55% (p\u2009=\u20090.00018). Furthermore, eight (6.3%) patients had symptoms related to pericardial effusion and were considered as cases with pericardial effusion \u2265 grade 3. The cumulative incidence of pericardial effusion \u2265 grade 3 was higher in patients with pericardium V30\u2009&gt;\u200965.80% (<jats:italic>p<\/jats:italic>\u2009=\u20090.00028), V40\u2009&gt;\u200955.35% (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), and V60\u2009&gt;\u200924.70% (<jats:italic>p<\/jats:italic>\u2009=\u20090.0021). Multivariate analyses showed the above dose-volume parameters predicted the risk of pericardial effusion in esophageal cancer.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Dose-volume parameters predicting the risk of pericardial effusion were identified in esophageal cancer treated with definitive concurrent chemotherapy and IMRT. They could be applied as constraints of IMRT for esophageal cancer.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13014-020-01498-3","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T08:02:54Z","timestamp":1582790574000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal cancer"],"prefix":"10.1186","volume":"15","author":[{"given":"Tzu-Hui","family":"Pao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Lun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Jung","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Wei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yau-Lin","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forn-Chia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"issue":"6","key":"1498_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1498_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","volume":"15","author":"T Conroy","year":"2014","unstructured":"Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial. Lancet Oncol. 2014;15(3):305\u201314.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1498_CR3","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1001\/jamaoncol.2017.1598","volume":"3","author":"M Suntharalingam","year":"2017","unstructured":"Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic L, Konski A, et al. Effect of the addition of Cetuximab to paclitaxel, Cisplatin, and radiation therapy for patients with esophageal Cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol. 2017;3(11):1520\u20138.","journal-title":"JAMA Oncol"},{"issue":"2","key":"1498_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1053\/j.gastro.2017.09.048","volume":"154","author":"DH Ilson","year":"2018","unstructured":"Ilson DH, van Hillegersberg R. Management of Patients with Adenocarcinoma or squamous Cancer of the esophagus. Gastroenterology. 2018;154(2):437\u201351.","journal-title":"Gastroenterology"},{"issue":"1","key":"1498_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.radonc.2012.04.016","volume":"104","author":"A Konski","year":"2012","unstructured":"Konski A, Li T, Christensen M, Cheng JD, Yu JQ, Crawford K, et al. Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother Oncol. 2012;104(1):72\u20137.","journal-title":"Radiother Oncol"},{"issue":"1","key":"1498_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.radonc.2014.11.037","volume":"114","author":"JC Beukema","year":"2015","unstructured":"Beukema JC, van Luijk P, Widder J, Langendijk JA, Muijs CT. Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer? Radiother Oncol. 2015;114(1):85\u201390.","journal-title":"Radiother Oncol"},{"issue":"3","key":"1498_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ijrobp.2013.07.008","volume":"87","author":"J Fukada","year":"2013","unstructured":"Fukada J, Shigematsu N, Takeuchi H, Ohashi T, Saikawa Y, Takaishi H, et al. Symptomatic pericardial effusion after chemoradiation therapy in esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2013;87(3):487\u201393.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1498_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.ijrobp.2007.10.056","volume":"70","author":"X Wei","year":"2008","unstructured":"Wei X, Liu HH, Tucker SL, Wang S, Mohan R, Cox JD, et al. Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008;70(3):707\u201314.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1498_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12885-019-5421-y","volume":"19","author":"Y Hayashi","year":"2019","unstructured":"Hayashi Y, Iijima H, Isohashi F, Tsujii Y, Fujinaga T, Nagai K, et al. The heart's exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer: a retrospective cohort study. BMC Cancer. 2019;19(1):195.","journal-title":"BMC Cancer"},{"issue":"12","key":"1498_CR10","first-page":"7389","volume":"34","author":"K Tamari","year":"2014","unstructured":"Tamari K, Isohashi F, Akino Y, Suzuki O, Seo Y, Yoshioka Y, et al. Risk factors for pericardial effusion in patients with stage I esophageal cancer treated with chemoradiotherapy. Anticancer Res. 2014;34(12):7389\u201393.","journal-title":"Anticancer Res"},{"issue":"6","key":"1498_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00066-016-0956-1","volume":"192","author":"I Ogino","year":"2016","unstructured":"Ogino I, Watanabe S, Iwahashi N, Kosuge M, Sakamaki K, Kunisaki C, et al. Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer. Strahlenther Onkol. 2016;192(6):359\u201367.","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"1498_CR12","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.ijrobp.2010.06.033","volume":"81","author":"K Kato","year":"2011","unstructured":"Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81(3):684\u201390.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1498_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijrobp.2008.10.075","volume":"75","author":"M Morota","year":"2009","unstructured":"Morota M, Gomi K, Kozuka T, Chin K, Matsuura M, Oguchi M, et al. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2009;75(1):122\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1498_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","volume":"79","author":"M Feng","year":"2011","unstructured":"Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79(1):10\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1498_CR15","unstructured":"Atlases for Organs at Risk (OARs) in Thoracic Radiation Therapy. Radiation Therapy Oncology Group (RTOG) 2011. https:\/\/www.rtog.org\/LinkClick.aspx?fileticket=qlz0qMZXfQs%3d&tabid=361. Accessed 12 Nov 2018."},{"issue":"3","key":"1498_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/jrr\/rry029","volume":"59","author":"N Takata","year":"2018","unstructured":"Takata N, Kataoka M, Hamamoto Y, Tsuruoka S, Kanzaki H, Uwatsu K, et al. Risk factors for pericardial effusion after chemoradiotherapy for thoracic esophageal cancer-comparison of four-field technique and traditional two opposed fields technique. J Radiat Res. 2018;59(3):291\u20137.","journal-title":"J Radiat Res"},{"issue":"6","key":"1498_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.cllc.2019.05.014","volume":"20","author":"JF Borkenhagen","year":"2019","unstructured":"Borkenhagen JF, Bergom C, Rapp CT, Klawikowski SJ, Rein LE, Gore EM. Dosimetric predictors of Cardiotoxicity in thoracic radiotherapy for lung Cancer. Clin Lung Cancer. 2019;20(6):435\u201341.","journal-title":"Clin Lung Cancer"},{"issue":"13","key":"1498_CR18","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.2016.71.6142","volume":"35","author":"RT Dess","year":"2017","unstructured":"Dess RT, Sun Y, Matuszak MM, Sun G, Soni PD, Bazzi L, et al. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung Cancer. J Clin Oncol. 2017;35(13):1395\u2013402.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1498_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","volume":"35","author":"SG Chun","year":"2017","unstructured":"Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung Cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35(1):56\u201362.","journal-title":"J Clin Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01498-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-020-01498-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-01498-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:30:31Z","timestamp":1614299431000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-020-01498-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1498"],"URL":"https:\/\/doi.org\/10.1186\/s13014-020-01498-3","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"18 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of National Cheng Kung University Hospital (reference number, A-ER-107-349). The informed consent was waived because of the retrospective nature of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}